Listed

KORU Medical Systems, Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 10, 2021 and accepted by EDGAR at Nov 10, 2021, 17:17 ET.

Share

Management's discussion and analysis

As filed, 2,795 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company issued an aggregate 20,988 shares of common stock to its non-employee directors during the three months ended September 30, 2021 under its 2021 Omnibus Equity Incentive Plan.

During the three months ended September 30, 2021, we issued 400,000 options at a weighted average exercise price of $3.17 to two new employees under the 2015 Stock Option Plan.

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

Issuer Purchases of Equity Securities

On November 16, 2020, the Company announced that its Board of Directors had authorized a stock repurchase program under which the Company may choose to purchase up to $10.0 million of its outstanding common stock through December 31, 2021. As of December 31, 2020, the Company had purchased 683,271 shares for an aggregate $3,499,358 pursuant to this program. No purchases have been made since that time, as we continue to evaluate our cash needs in connection with strategic planning under the leadership of our new Chief Executive Officer.

PART II – ITEM 6. EXHIBITS.

31.1 Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002
31.2 Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002
32.1 Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002
32.2 Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002
101.INS Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

- 24 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REPRO MED SYSTEMS, INC.
November 10, 2021 /s/ Linda Tharby
Linda Tharby, President and Chief Executive Officer (Principal Executive Officer)
November 10, 2021 /s/ Karen Fisher
Karen Fisher, Chief Financial Officer and Treasurer (Principal Financial Officer)

- 25 -

Controls and procedures

As filed, 1,350 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the three months ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 490 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form 10-K for the year ended December 31, 2020, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2020.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$6.0mus-gaap:Revenues
Revenue9 months2021-01-01 to 2021-09-30$17.0mus-gaap:Revenues
Cost of revenue3 months2021-07-01 to 2021-09-30$2.5mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-01-01 to 2021-09-30$7.1mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-07-01 to 2021-09-30$3.5mus-gaap:GrossProfit
Gross profit9 months2021-01-01 to 2021-09-30$9.9mus-gaap:GrossProfit
Research and development3 months2021-07-01 to 2021-09-30$800.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$1.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-01 to 2021-09-30$3.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$13.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30−$1.3mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$4.9mus-gaap:OperatingIncomeLoss
Income tax3 months2021-07-01 to 2021-09-30−$238.1kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30−$1.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30−$1.1mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$3.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.02us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30−$0.08us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30−$0.02us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30−$0.08us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3044,322,335 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3044,510,021 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30−$3.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$301.7kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2021-09-30$26.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$37.7mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$41.4mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$4.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$4.6mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$36.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001161697-21-000525. Last ingested by Listed: Nov 11, 2026, 02:24 ET. Listed shows no prices and gives no investment advice.